{"product_id":"proteogenix-budoprutug-biosimilar-anti-cd19-mab-research-grade","title":"Budoprutug Biosimilar – Anti-CD19 mAb – Research Grade","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eBudoprutug Biosimilar – Anti-CD19 mAb – Research Grade is a novel therapeutic antibody that targets the CD19 protein, which is found on the surface of B cells. This biosimilar is designed to mimic the structure and activity of the original anti-CD19 monoclonal antibody, while providing a more affordable and accessible option for researchers. In this article, we will delve into the structure, activity, and potential applications of this antibody.\u003c\/p\u003e \u003ch3\u003eStructure of Budoprutug Biosimilar – Anti-CD19 mAb\u003c\/h3\u003e \u003cp\u003eBudoprutug Biosimilar – Anti-CD19 mAb is a monoclonal antibody, meaning it is produced by a single clone of immune cells. The antibody is composed of two identical heavy chains and two identical light chains, each with a unique variable region that recognizes and binds to the CD19 protein. The constant regions of the antibody allow for interactions with other immune cells and molecules, leading to the activation of immune responses.\u003c\/p\u003e \u003cp\u003eThe variable regions of the antibody are responsible for its specificity and binding affinity to the CD19 protein. Through genetic engineering techniques, the variable regions of the original anti-CD19 antibody have been replicated to create the biosimilar version. This ensures that the biosimilar has the same binding properties and activity as the original antibody.\u003c\/p\u003e \u003ch3\u003eActivity of Budoprutug Biosimilar – Anti-CD19 mAb\u003c\/h3\u003e \u003cp\u003eThe primary function of Budoprutug Biosimilar – Anti-CD19 mAb is to target and bind to the CD19 protein on the surface of B cells. This binding leads to the activation of various immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\u003c\/p\u003e \u003cp\u003eADCC is a process in which the antibody binds to the CD19 protein and attracts immune cells, such as natural killer (NK) cells, to the site. These immune cells then release cytotoxic substances that destroy the B cells, leading to a reduction in CD19 levels. Similarly, CDC involves the activation of the complement system, which leads to the formation of pores on the B cells, causing them to burst and die.\u003c\/p\u003e \u003cp\u003eIn addition to these mechanisms, Budoprutug Biosimilar – Anti-CD19 mAb also has the potential to induce apoptosis (programmed cell death) in B cells, further reducing CD19 levels. This activity makes the antibody an effective therapeutic option for conditions characterized by excessive B cell activity, such as autoimmune diseases and certain types of cancer.\u003c\/p\u003e \u003ch3\u003eApplications of Budoprutug Biosimilar – Anti-CD19 mAb\u003c\/h3\u003e \u003cp\u003eBudoprutug Biosimilar – Anti-CD19 mAb has a wide range of potential applications in both research and clinical settings. In research, the biosimilar can be used to study the role of CD19 in various diseases and to develop new treatments targeting this protein. It can also be used as a tool to study the mechanisms of ADCC and CDC, as well as the role of B cells in immune responses.\u003c\/p\u003e \u003cp\u003eIn clinical settings, Budoprutug Biosimilar – Anti-CD19 mAb has the potential to be used as a therapeutic option for conditions such as B cell lymphomas, leukemias, and autoimmune diseases. It can also be used in combination with other therapies to enhance their effectiveness, or as a maintenance therapy to prevent disease relapse.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eBudoprutug Biosimilar – Anti-CD19 mAb – Research Grade is a novel antibody that targets the CD19 protein on B cells. Its structure and activity have been carefully designed to mimic those of the original anti-CD19 antibody, making it an effective and affordable option for researchers. With its potential applications in both research and clinical settings, this biosimilar has the potential to advance our understanding and treatment of various diseases.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA2110. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: Budoprutug Biosimilar – Anti-CD19 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: \u0026gt;95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA2110.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357707673940,"sku":"ABM133953-1","price":140.0,"currency_code":"USD","in_stock":true},{"title":"100ug","offer_id":57357707706708,"sku":"ABM133953-2","price":201.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":57357707739476,"sku":"ABM133953-3","price":412.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/sds-validation-1-budoprutug-biosimilar-anti-cd19-mab-research-grade_b2c9aa88-7d3d-4523-a7e6-ef50137c5085.jpg?v=1790890932","url":"https:\/\/www.abmium.com\/fr\/products\/proteogenix-budoprutug-biosimilar-anti-cd19-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}